Furthermore, our study raises the intriguing possibility that, in diseases associated with clock dysfunction, such as hypertension and type 2 diabetes [9–11], short-term, pulsatile treatment with T4 might permit one to modulate circadian activity in diseased peripheral tissues in a therapeutically beneficial manner, therefore providing a novel strategy for differential endocrine “peripheral clock therapy”. This evidence concerns the gene CLOCK and type 2 diabetes mellitus.